Table 1. Features at presentation... | American Society of Hematology

Table 1.

Features at presentation

Parameter	No. of patients (n = 698)	Age (y)					P value for trend
Parameter	No. of patients (n = 698)	0 (n = 57)	1 (n = 95)	2-4 (n = 140)	5-9 (n = 178)	10-15 (n = 228)	P value for trend
Gender
Male	384	60	55	49	60	54	.9
Female	314	40	45	51	40	46
Type of disease
De novo	653	91	96	89	95	95	.1
Secondary	35	5	3	10	3	4	.2
MDS	10	4	1	1	2	1	.4
Initial WCC × 10⁹/L (n = 681)
Below 10	279	26	31	46	44	41	.6
10-99	298	47	53	44	38	41
100 or above	104	25	14	7	16	17
FAB type (n = 673)
M0	22	0	2	3	2	5	.03
M1	83	4	13	11	10	16	.04
M2	203	16	13	25	44	30	.005
M3	53	0	2	6	10	11	< .001
M4	108	12	11	14	18	18	.1
M5	112	42	26	19	6	11	< .001
M6	12	0	3	2	1	2	.9
M7	43	14	18	10	2	< 1	< .001
RAEBt	37	9	9	6	3	4	.06
Performance status
0	155	21	19	18	21	27	< .001
1	297	37	29	44	47	45
2	177	30	32	27	25	21
3	56	12	17	9	4	6
4	13	0	3	2	3	0
CNS involvement (n = 673)
Yes	44	12	15	5	3	5	.01
No	629	84	80	92	93	92
Down syndrome (n = 688)
Yes	35	0	17	11	1	< 1	< .001
No	653	98	82	86	98	98
Abnormal 11q23 (n = 564)
Yes	61	25	18	9	6	3	< .001
No	503	54	63	70	78	77
Cytogenetic risk group (n = 564)
Favorable	137	2	6	18	28	25	< .001
Intermediate	354	68	60	46	47	48
Adverse	73	9	15	15	9	7
Remission status after course 1 (n = 617)
CR	421	67	62	58	62	58	.004
PR	117	14	23	20	15	14
RD	79	0	5	9	13	17
Risk group (n = 585)
Good	164	2	6	21	32	31	.03
Standard	301	72	57	45	37	34
Poor	120	4	18	17	17	21

Parameter	No. of patients (n = 698)	Age (y)					P value for trend
Parameter	No. of patients (n = 698)	0 (n = 57)	1 (n = 95)	2-4 (n = 140)	5-9 (n = 178)	10-15 (n = 228)	P value for trend
Gender
Male	384	60	55	49	60	54	.9
Female	314	40	45	51	40	46
Type of disease
De novo	653	91	96	89	95	95	.1
Secondary	35	5	3	10	3	4	.2
MDS	10	4	1	1	2	1	.4
Initial WCC × 10⁹/L (n = 681)
Below 10	279	26	31	46	44	41	.6
10-99	298	47	53	44	38	41
100 or above	104	25	14	7	16	17
FAB type (n = 673)
M0	22	0	2	3	2	5	.03
M1	83	4	13	11	10	16	.04
M2	203	16	13	25	44	30	.005
M3	53	0	2	6	10	11	< .001
M4	108	12	11	14	18	18	.1
M5	112	42	26	19	6	11	< .001
M6	12	0	3	2	1	2	.9
M7	43	14	18	10	2	< 1	< .001
RAEBt	37	9	9	6	3	4	.06
Performance status
0	155	21	19	18	21	27	< .001
1	297	37	29	44	47	45
2	177	30	32	27	25	21
3	56	12	17	9	4	6
4	13	0	3	2	3	0
CNS involvement (n = 673)
Yes	44	12	15	5	3	5	.01
No	629	84	80	92	93	92
Down syndrome (n = 688)
Yes	35	0	17	11	1	< 1	< .001
No	653	98	82	86	98	98
Abnormal 11q23 (n = 564)
Yes	61	25	18	9	6	3	< .001
No	503	54	63	70	78	77
Cytogenetic risk group (n = 564)
Favorable	137	2	6	18	28	25	< .001
Intermediate	354	68	60	46	47	48
Adverse	73	9	15	15	9	7
Remission status after course 1 (n = 617)
CR	421	67	62	58	62	58	.004
PR	117	14	23	20	15	14
RD	79	0	5	9	13	17
Risk group (n = 585)
Good	164	2	6	21	32	31	.03
Standard	301	72	57	45	37	34
Poor	120	4	18	17	17	21

Figures for each age group are column percentages.

MDS indicates myelodysplastic syndrome; WCC, white cell count; RAEBt, refractory anemia with excess blasts in transformation; CNS, central nervous system; CR, complete remission; PR, partial remission; RD, resistant disease.

View Large

This Feature Is Available To Subscribers Only